Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Follicular Lymphoma Clinical Trials

A listing of Follicular Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (106) clinical trials

The purpose of this study is to evaluate the safety and tolerability of INCB050465 when combined with bendamustine and obinutuzumab in relapsed or refractory follicular lymphoma (FL).

Phase

This is a Phase 1b, open-label, single-arm combination study with a dose escalation phase (Part 1) followed by a dose expansion phase (Part 2). The study will enroll approximately 75 patients. A standard 3+3 dose escalation design will be used for Part 1. The DLT period will be the 21 ...

Phase

CD19+ CAR T Cells for Lymphoid Malignancies

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to a Dose Level of genetically changed T-cells based on when you begin to receive the cell product. Up to 4 dose levels of T-cells will be tested. Up to 3 ...

Phase

A Phase 1 Multiple Ascending Dose Study of DS-3201b in Japanese Subjects With Lymphomas

This will be a First-in-Human, Phase 1, multi-center, non-randomized, open label study of DS-3201b, Histone-lysine N-methyltransferase EZH1/2 dual inhibitor to assess its safety and tolerability, identify a maximum tolerated dose (MTD)/ tentative recommended phase 2 dose (RP2D), and assess its pharmacokinetic/dynamic properties in Japanese subjects with Non-Hodgkin's Lymphoma.

Phase

Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A

This study will involve participants with a condition called Follicular NonHodgkin Lymphoma (Follicular Lymphoma). The main purpose of this study is to see if it is safe to give drug Nivolumab before and in combination with drug Rituximab and to see how effective Nivolumab is in patients who have had ...

Phase

Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

This study will evaluate the preliminary safety, tolerability, and dose-limiting toxicities (DLTs) of Sym021, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody (mAb) . The goal is to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalating doses of Sym021 when administered once ...

Phase

Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma

This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and anti-lymphoma activity of an autologous T cell product (ACTR707) in combination with rituximab in subjects with refractory or relapsed CD20+ B cell lymphoma.

Phase

Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma

This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and efficacy of an autologous T-cell product expressing ACTR in combination with rituximab in subjects with refractory or relapsed CD20+ B-cell lymphoma.

Phase

Durvalumab in Pediatric and Adolescent Patients

This trial will assess the safety and tolerability of Durvalumab in children and adolescents and also study how Durvalumab is processed in their bodies.

Phase

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

The purpose of this study is to test the safety of giving the patient special cells from a donor called "Modified T-cells". The goal is to find a safe dose of modified T-cells for patients with relapsed B cell leukemia or lymphoma after a blood SCT. The investigators also want ...

Phase